CoChat
Sign Up
Cited by 73Pancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research AdvancesSalivary Gland Tumors Diagnosis and Treatment

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis

Open access
Winter, Jordan M., Jiang, Wei, Basturk, Olca, Mino-Kenudson, Mari, Fong, Zhi Ven, Tan, Wei Phin, Lavu, Harish, Vollmer, Charles M., Furth, Emma E., Haviland, Dana, Klimstra, David S., Jarnagin, William R., Lillemoe, Keith D., Yeo, Charles J., Castillo, Carlos Fernandez-Del, Allen, Peter J.·2016·Annals of Surgery
DOI 10.1097/sla.0000000000001319PMC PMC4957241
Open this paper in CoChat — free account

Abstract

BACKGROUND: Early invasive carcinoma may be encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The natural history of these early invasive lesions is unknown. METHODS: Pancreatic surgical databases from 4 high-volume centers were queried for IPMNs, with invasive components measuring 20 mm or less. All cases were reviewed by GI gastrointestinal pathologists, and pathologic features were analyzed to identify predictors of recurrence and survival. RESULTS: A total of 70 small IPMN-associated invasive carcinomas (≤20-mm invasion) were identified, comprising 25% of resected IPMN-associated carcinomas (n = 280). Most of these small invasive cancers were multifocal (66%), less than 10 mm in size (73%), and arose in the setting of a main duct IPMN (96%). The most common adenocarcinoma subtypes were tubular (57%) and colloid (29%). Lymph node metastases were present in 19% of cases and 23% were T3 lesions. The overall recurrence rate was 24% (n = 17), and the median time to recurrence was 16 months (range: 4-132 months). Median and 5-year survival rates were 99 months and 59%. Recurrence patterns of invasive disease were local in 35%, distant in 47%, and both in 18%. Lymphatic spread and T3 stage were predictive of recurrence (univariate, P = 0.006), whereas tubular carcinoma type was the most predictive of poor overall survival (multivariate hazard ratio = 3.7, P = 0.04). CONCLUSIONS: This study represents the largest multi-institutional experience of resected small IPMN-associated carcinoma. Although these malignancies may frequently be cured with resection, recurrence risk is significant. Lymphatic spread, increased T stage, and tubular type carcinoma were associated with the poorest outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000001319

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Hruban, 2008, Update on pancreatic intraepithelial neoplasia, Int J Clin Exp Pathol, 1, 306
  2. He, 2013, Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?, J Am Coll Surg, 216, 657, 10.1016/j.jamcollsurg.2012.12.026 · DOI
  3. Lafemina, 2013, Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation, Ann Surg Oncol, 20, 440, 10.1245/s10434-012-2702-y · DOI
  4. Ohtsuka, 2012, Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas, Am J Surg, 204, 44, 10.1016/j.amjsurg.2011.04.007 · DOI
  5. Shi, 2012, Intraductal papillary mucinous neoplasm, Hum Pathol, 43, 1, 10.1016/j.humpath.2011.04.003 · DOI
  6. Poultsides, 2010, Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas, Ann Surg, 251, 470, 10.1097/SLA.0b013e3181cf8a19 · DOI
  7. Yopp, 2011, Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma, Ann Surg, 253, 968, 10.1097/SLA.0b013e318214bcb4 · DOI
  8. House, 2007, Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer, J Gastrointest Surg, 11, 1549, 10.1007/s11605-007-0243-7 · DOI
  9. Mino-Kenudson, 2011, Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes, Gut, 60, 1712, 10.1136/gut.2010.232272 · DOI
  10. Wu, 2011, Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways, Proc Natl Acad Sci U S A, 108, 21188, 10.1073/pnas.1118046108 · DOI
  11. Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
  12. Su, 1999, Germline and somatic mutations of the STK11(LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers, Am J Pathol, 154, 1835, 10.1016/S0002-9440(10)65440-5 · DOI
  13. Sato, 2001, STK11(LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas, Am J Pathol, 159, 2017, 10.1016/S0002-9440(10)63053-2 · DOI
  14. Canto, 2006, Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study, Clin Gastroenterol Hepatol, 4, 766, 10.1016/j.cgh.2006.02.005 · DOI · Paper page
  15. Oettle, 2013, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, 310, 1473, 10.1001/jama.2013.279201 · DOI
  16. Regine, 2011, Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup(RTOG 9704 phase III trial, Ann Surg Oncol, 18, 1319, 10.1245/s10434-011-1630-6 · DOI
  17. Winter, 2006, 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience, J Gastrointest Surg, 10, 1199, 10.1016/j.gassur.2006.08.018 · DOI
  18. Lee, 2006, Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size, J Thorac Cardiovasc Surg, 132, 1382, 10.1016/j.jtcvs.2006.08.053 · DOI
  19. Elkin, 2005, The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999, Cancer, 104, 1149, 10.1002/cncr.21285 · DOI
  20. Laffan, 2008, Prevalence of unsuspected pancreatic cysts on MDCT, AJR Am J Roentgenol, 191, 802, 10.2214/AJR.07.3340 · DOI
  21. Furukawa, 2005, Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study, Virchows Arch, 447, 794, 10.1007/s00428-005-0039-7 · DOI
  22. Nakagohri, 2002, Long-term surgical outcome of noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma of the pancreas, World J Surg, 26, 1166, 10.1007/s00268-002-6254-3 · DOI
  23. Nara, 2008, Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms, Am J Surg Pathol, 32, 243, 10.1097/PAS.0b013e3181484f1e · DOI
  24. Kim, 2011, Prognostic relevance of pathologic subtypes and minimal invasion in intraductal papillary mucinous neoplasms of the pancreas, Tumour Biol, 32, 535, 10.1007/s13277-010-0148-z · DOI
  25. Stelow, 2009, Mucus rupture (extrusion) and duct expansion(expansive growth are not diagnostic of minimal invasion when seen with intraductal papillary mucinous neoplasms, Am J Surg Pathol, 33, 320, 10.1097/PAS.0b013e3181861bcd · DOI
  26. Matthaei, 2012, Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas, Ann Surg, 255, 326, 10.1097/SLA.0b013e3182378a18 · DOI
  27. Okada, 2005, Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection, J Thorac Cardiovasc Surg, 129, 87, 10.1016/j.jtcvs.2004.04.030 · DOI
  28. Friberg, 1997, On the growth rates of human malignant tumors: implications for medical decision making, J Surg Oncol, 65, 284, 10.1002/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2 · DOI
  29. Rhim, 2012, EMT and dissemination precede pancreatic tumor formation, Cell, 148, 349, 10.1016/j.cell.2011.11.025 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Winter, J. M., Jiang, W., Basturk, O., Mino-Kenudson, M., Fong, Z. V., Tan, W. P., Lavu, H., Vollmer, C. M., Furth, E. E., Haviland, D., Klimstra, D. S., Jarnagin, W. R., Lillemoe, K. D., Yeo, C. J., Castillo, C. F.-D., & Allen, P. J.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
ORCID
Venue
Annals of Surgery
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-04
Volume
263
Issue
4
Pages
793-801
ISSN
0003-4932 (ISSN-L)
DOI
10.1097/sla.0000000000001319
PMC
PMC4957241
OpenAlex
W1473071129
Cited by
73
References
3
Citations by year
2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 9 · 2016: 9
FWCI
3.79
Type
journal article
Language
en
Open access
Locations
  • Annals of Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Salivary Gland Tumors Diagnosis and Treatment
Keywords
intraductal papillary mucinous neoplasm, pancreatic cancer, early invasive carcinoma, recurrence, survival, pancreatic resection, lymph node metastasis, tubular adenocarcinoma, colloid adenocarcinoma, prognostic factors, multifocal tumors
MeSH terms
Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms, Retrospective Studies, Survival Rate, Logistic Models, Proportional Hazards Models, Carcinoma, Pancreatic Ductal, Tumor Burden, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review